Brought to you by 
NeuroDerm nets $41.5mm in Nasdaq IPO
18 Nov 2014
Executive Summary
Ten-year-old Israeli biotech NeuroDerm Ltd. (reformulates existing neurological disease therapeutics) netted $41.5mm in its Nasdaq initial public offering of 4.5mm ordinary shares at $10, below its anticipated $13-16 range.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
-
Medical Devices
- Infusion Therapy Equipment and Supplies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeuroDerm nets $41.5mm in Nasdaq IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice